Elizabeth A. HunspergerSutee YoksanPhilippe BuchyVinh Chau NguyenShamala D. SekaranDelia A. EnriaJose L. PelegrinoSusana VázquezHarvey ArtsobMichael DrebotDuane J. GublerScott B. HalsteadMaría G. GuzmánHarold S. MargolisCarl Michael NathansonNidia R Rizzo LicKovi E. BessoffSrisakul KliksRosanna W. PeelingCenters for Disease Control and Prevention San JuanMahidol UniversityInstitut Pasteur du CambodgeCho Quan HospitalUniversity of MalayaInstituto Nacional de Enfermedades Virales Humanas Dr. Julio I. MaizteguiInstituto de Medicina Tropical Pedro KouriAgence de la sante publique du CanadaUniversity of Hawaii at ManoaPediatric Dengue Vaccine InitiativeOrganisation Mondiale de la Sante2018-09-132018-09-132009-03-01Emerging Infectious Diseases. Vol.15, No.3 (2009), 436-44010806059108060402-s2.0-63849340687https://repository.li.mahidol.ac.th/handle/20.500.14594/28186Anti-dengue virus immunoglobulin M kits were evaluated. Test sensitivities were 21%-99% and specificities were 77%-98% compared with reference ELISAs. False-positive results were found for patients with malaria or past dengue infections. Three ELISAs showing strong agreement with reference ELISAs will be included in the World Health Organization Bulk Procurement Scheme.Mahidol UniversityMedicineArticleSCOPUS10.3201/eid1503.080923